SG10201804305SA - Stabilized ophthalmic galactomannan formulations - Google Patents

Stabilized ophthalmic galactomannan formulations

Info

Publication number
SG10201804305SA
SG10201804305SA SG10201804305SA SG10201804305SA SG10201804305SA SG 10201804305S A SG10201804305S A SG 10201804305SA SG 10201804305S A SG10201804305S A SG 10201804305SA SG 10201804305S A SG10201804305S A SG 10201804305SA SG 10201804305S A SG10201804305S A SG 10201804305SA
Authority
SG
Singapore
Prior art keywords
formulations
stabilized ophthalmic
stabilized
ophthalmic
guar
Prior art date
Application number
SG10201804305SA
Inventor
Howard Allen Ketelson
James W Davis
David L Meadows
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of SG10201804305SA publication Critical patent/SG10201804305SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Stabilized Ophthalmic Galactomannan Formulations The present invention relates to viscosity stabilized ophthalmic formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise 5 galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a diol alcohol such as sorbitol and, optionally, a pharmaceutically acceptable divalent cation salt such as magnesium chloride. 10 (No suitable figure)
SG10201804305SA 2010-05-05 2011-05-04 Stabilized ophthalmic galactomannan formulations SG10201804305SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33151110P 2010-05-05 2010-05-05

Publications (1)

Publication Number Publication Date
SG10201804305SA true SG10201804305SA (en) 2018-06-28

Family

ID=44626461

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2012081386A SG185422A1 (en) 2010-05-05 2011-05-04 Stabilized ophthalmic galactomannan formulations
SG10201804305SA SG10201804305SA (en) 2010-05-05 2011-05-04 Stabilized ophthalmic galactomannan formulations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2012081386A SG185422A1 (en) 2010-05-05 2011-05-04 Stabilized ophthalmic galactomannan formulations

Country Status (16)

Country Link
US (2) US20110275593A1 (en)
EP (1) EP2566447B1 (en)
JP (1) JP5794744B2 (en)
KR (2) KR20130060228A (en)
CN (2) CN102939074A (en)
AR (1) AR081015A1 (en)
AU (1) AU2011248129B2 (en)
BR (1) BR112012028308B1 (en)
CA (1) CA2798069C (en)
ES (1) ES2809304T3 (en)
MX (1) MX2012012826A (en)
NZ (1) NZ603345A (en)
SG (2) SG185422A1 (en)
TW (1) TWI606841B (en)
WO (1) WO2011140203A2 (en)
ZA (1) ZA201208199B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101592872B1 (en) * 2008-04-26 2016-02-12 알콘 리서치, 리미티드 Polymeric artificial tear system
TWI492769B (en) * 2009-09-23 2015-07-21 Alcon Res Ltd Injectable aqueous ophthalmic composition and method of use therefor
TW201336527A (en) * 2012-02-10 2013-09-16 Alcon Res Ltd Aqueous pharmaceutical composition with enhanced stability
UA113434C2 (en) * 2012-05-04 2017-01-25 Алкон Рісерч, Лтд. Ophthalmic compositions with improved dessication protection and retention
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
JP7057290B2 (en) 2016-06-27 2022-04-19 アキリオン ファーマシューティカルズ，インコーポレーテッド Quinazoline and indole compounds for the treatment of medical disorders
US11260035B2 (en) 2016-10-12 2022-03-01 Ps Therapies Ltd Topical compositions and methods of use thereof
WO2018071619A1 (en) * 2016-10-12 2018-04-19 Ps Therapies Ltd Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
US11583496B2 (en) 2016-10-12 2023-02-21 PS Therapy Inc. Drug vehicle compositions and methods of use thereof
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
EP3841086A4 (en) 2018-08-20 2022-07-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
WO2020081723A1 (en) 2018-10-16 2020-04-23 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
TWI757773B (en) * 2019-06-28 2022-03-11 瑞士商愛爾康公司 Ophthalmic compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8028A (en) * 1851-04-08 Hokse-poweb
US4136173A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
DE3827561C1 (en) * 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5505953A (en) * 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
EP0999825B1 (en) * 1997-07-29 2003-10-01 Alcon Laboratories, Inc. Ophthalmic compositions containing galactomannan polymers and borate
GB9808461D0 (en) * 1998-04-22 1998-06-17 Innovative Tech Ltd Solid borate-diol interaction products
US7084130B2 (en) * 2001-12-11 2006-08-01 Alcon, Inc. Intraocular irrigating solution having improved flow characteristics
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
US20100021561A1 (en) * 2006-09-21 2010-01-28 Chowhan Masood A Self-preserved aqueous pharmaceutical compositions
TWI434926B (en) 2006-12-11 2014-04-21 Alcon Res Ltd Use of peo-pbo block copolymers in ophthalmic compositions
AR066901A1 (en) * 2007-05-18 2009-09-23 Alcon Mfg Ltd PHODFOLIPID COMPOSITIONS FOR THE CLOSURE OF CONTACT LENSES AND PRESERVATION OF PHARMACEUTICAL COMPOSITIONS
KR101592872B1 (en) * 2008-04-26 2016-02-12 알콘 리서치, 리미티드 Polymeric artificial tear system
MX2011007714A (en) 2009-02-05 2011-12-06 Alcon Res Ltd Process for purifying guar.

Also Published As

Publication number Publication date
AR081015A1 (en) 2012-05-30
US8846641B2 (en) 2014-09-30
ZA201208199B (en) 2014-01-29
NZ603345A (en) 2014-12-24
TWI606841B (en) 2017-12-01
CA2798069A1 (en) 2011-11-10
JP5794744B2 (en) 2015-10-14
BR112012028308B1 (en) 2021-09-28
CN102939074A (en) 2013-02-20
KR20130060228A (en) 2013-06-07
KR20180001587A (en) 2018-01-04
AU2011248129B2 (en) 2014-10-09
WO2011140203A3 (en) 2012-04-19
BR112012028308A2 (en) 2016-11-01
SG185422A1 (en) 2012-12-28
US20110275593A1 (en) 2011-11-10
EP2566447A2 (en) 2013-03-13
EP2566447B1 (en) 2020-07-15
AU2011248129A1 (en) 2012-11-29
MX2012012826A (en) 2013-01-28
CN106389325A (en) 2017-02-15
ES2809304T3 (en) 2021-03-03
TW201141524A (en) 2011-12-01
CA2798069C (en) 2016-07-05
US20130244971A1 (en) 2013-09-19
WO2011140203A2 (en) 2011-11-10
JP2013525493A (en) 2013-06-20

Similar Documents

Publication Publication Date Title
SG10201804305SA (en) Stabilized ophthalmic galactomannan formulations
AR112286A2 (en) POLYMERIC SYSTEM OF ARTIFICIAL TEARS
MX2014009757A (en) Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy.
MX2013002422A (en) Salts of lorcaserin with optically active acids.
MX2013001677A (en) Stable formulations of linaclotide.
PH12014502571A1 (en) Ophthalmic compositions with improved dessication protection and retention
IN2012DN02177A (en)
IN2012DN02730A (en)
IN2012DN00754A (en)
GB201106743D0 (en) Novel compounds
MX344473B (en) Semisolid aqueous pharmaceutical composition containing tapentadol.
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
MX345404B (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-m ethylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate.
MY162175A (en) Aqueous drug delivery system
TN2012000261A1 (en) Aerosol formulation for copd
TW200718698A (en) Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
EA201591188A1 (en) DELIVERY OF GLETIRAMER ACETATE THROUGH THE SLIGHTY SHELL
MX2012006265A (en) Hypersulfated disaccharide formulations.
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
WO2011076840A3 (en) Aerosol formulation for copd
MX2015007794A (en) Oral transmucosal delivery of glatiramer acetate.
MX2014004210A (en) 2-oxo-piperidinyl derivatives.
BR112012020828A2 (en) pharmaceutical preparation containing miramistin
MX2012012978A (en) Method of producing pleurodesis.
EP2780009A4 (en) Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations